What do systematic reviews say?

Pembrolizumab vs chemotherapy alone

Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).

• Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
  RR 0.66 [0.39, 1.1]
  1 study · 521 participants
  Low